Camson Biotech reports standalone 9M FY2016 Revenue of Rs.

3,104 Lakhs;
Enhanced focus of receivables management and cost optimization
Standalone Performance Highlights: 9M FY2016
Net Sales of Rs. 3,104 Lakhs
Gross Profit of Rs. 2,774 Lakhs; Margins at 89%
Bangalore, India, February 10, 2016 Camson Biotechnologies Limited (Camson Biotech
or the Company), India's first integrated IPR driven agricultural biotechnology company,
announces its standalone Q3 and Nine month results for FY2016.
Update on the Demerger of the Seeds business: Consequent to receipt of approval for the
Scheme of Arrangement (Scheme) by the Honourable High Court of Karnataka vide its
order dated July 31st, 2015, the Scheme became effective from September 1st, 2015. Post
filing of the Court order with the office of the Registrars of Companies, Camson Biotech had
set the record date for the demerger as September 22nd, 2015. This is defined for the
purpose of entitlement of shares of Camson Seeds Limited (Camson Seeds), which is to be
listed separately in due course. As on 14th November 2015, Board of Directors of Camson
Seeds had approved allotment of shares to all who are the shareholders of Camson Biotech
as on the record date. Accordingly, shares of Camson Seeds have been credited into the
Demat accounts of the shareholders on 18th January 2016 and 20th January 2016 by CDSL
and NSDL, respectively.
The Company now operates in a single segment, i.e. Agri-Biotech. Q3 FY2016 results have
been presented for the Agri-Biotech business and the results relating to previous
quarter/period/year are not comparable.
Nine Month FY2016 Performance: Standalone revenue during the first nine months FY2016
was Rs. 3,104 lakh at a Gross Margin of 89%. Last quarters performance was severely
impacted by unfavourable industry environment. Demand in Punjab and Haryana, which
constitutes one of our largest end markets, was impacted by unfavourable monsoon which
led to a decline in commodity prices and high inventory levels. The bad weather conditions
in north India severely impacted cotton crop resulting in an overall decline in the demand
scenario. Markets in South India were impacted by drought leading to poor farmer
sentiment.
Camson Biotech has undertaken several corrective measures to counter the unfavourable
industry environment including consolidation of business and manpower. To manage the
receivables cycle, the Company bought back off season products inventory from dealers.
1|P ag e

This resulted in a decline in sales but enabled the Company keep the working capital cycle
under check. The Company also directed its marketing focus on well irrigated regions
instead of areas which are monsoon dependant.
Recent Corporate Developments:

During the quarter the Company launched Calzeb, an effective broad spectrum
fungicide that has both preventive and curative qualities.

Commenting the business and performance, Mr. Santosh Nair, CEO of Camson
Biotechnologies Limited said:
FY2016 continues to be a very challenging period for the Indian agriculture industry.
Deficient monsoon in North India and drought like situation in South India impacted the
overall revenues of the Company. In these tough times management refocused energy in
cost optimization and managing working capital efficiently. We expect to see results of
these initiatives from Q4 FY2016 onwards.
Trials for our Natural Fertilizer products are progressing well and we are quite excited with
the results and feedback. We expect to see meaningful results from this product line in
FY2017.
The Demerger of the Seeds business is now complete and we expect the Seeds entity to get
listed in coming weeks. We now have a focused operating and capital structure to capitalize
on the growth potential of the agri-biotech industry.
About Camson:
Camson Bio Technologies Limited (Camson or the Company) is India's first integrated
IPR driven agricultural biotechnology company. Founded in 1993, Camson is headquartered
in Bangalore, with primary focus on biotech R&D. The Company is a pioneer in zero residue
farming products, which uses secondary metabolites (biological origin) of microbes to kill /
inhibit pathogens, with no use of chemicals. It has been recognized by Deloitte as one the
fastest growing technology companies in 2015 and conferred the Technology Fast 500
award and awarded the Leaders of Tomorrow Award by ET Now & Indiamart 2014-15.

2|P ag e

Contact Details:
Camson Bio Technologies Limited (CIN: L85110KA1993PLC014944)
C-7, 7th Floor, Corporate Block, Golden Enclave, Old Airport Road, Bangalore - 560 017
Santosh R Nair
Camson Bio Technologies
Saket Somani
Churchgate Partners

info@camsonbiotechnologies.com
+91 80 4076 8900
Camson@churchgatepartnersindia.com
+91 22 6169 5988

Safe Harbor:
This release contains statements that contain forward looking statements including, but
without limitation, statements relating to the implementation of strategic initiatives, and
other statements relating to Camson Biotechs future business developments and economic
performance. While these forward looking statements indicate our assessment and future
expectations concerning the development of our business, a number of risks, uncertainties
and other unknown factors could cause actual developments and results to differ materially
from our expectations. These factors include, but are not limited to, general market, macroeconomic, governmental and regulatory trends, movements in currency exchange and
interest rates, competitive pressures, technological developments, changes in the financial
conditions of third parties dealing with us, legislative developments, and other key factors
that could affect our business and financial performance. Camson Biotech undertakes no
obligation to publicly revise any forward looking statements to reflect future / likely events or
circumstances.

3|P ag e